Allergan reaches historic BOTOX® milestone with 100 million vials

Allergan has announced it has reached a significant milestone in the history of BOTOX® by manufacturing the 100 millionth vial of the brand.

As the 100 millionth vial rolls off the production line this month, BOTOX® will be used for aesthetic and therapeutic use in 35 different indications, in 97 countries. 

In the aesthetics market, it is currently licensed for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) and/or; moderate to severe lateral canthal lines (crow's feet lines) seen at maximum smile and/or; moderate to severe forehead lines at maximum eyebrow elevation when the severity of the facial lines has an important psychological impact in adult patients.

Since the initial approval, it has expanded into different therapy areas. The neurotoxin is used by healthcare practitioners to treat various neurology and urology conditions.

The safety profile and quality of BOTOX® has been established in 148 clinical trials.

The global manufacturing site in Westport remains the sole location to produce and distribute the 100 million vials of BOTOX® worldwide. The air in the filling rooms is changed 200 times in an hour to maintain the quality of the product and every vial is 100% visually inspected.

Allergan is continuing to steer innovation through collaborations with researchers, scientists, physicians and academic bodies to find new uses for botulinum toxin, providing medical solutions for patients worldwide.

Mitchell Brin, SVP Global Drug Development & Chief Scientific Officer at Allergan commented, "After 30 years of studying this drug we have a large safety database and based upon our understanding of the mechanism of action and the safety profile, we are now moving into other disorders that I would say that two decades ago I would not have anticipated going into." .